A commentary on 'Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study'
Int J Surg. 2024 Mar 4.
doi: 10.1097/JS9.0000000000001299.
Online ahead of print.
1 Department of Hepato-Pancreato-biliary Surgery，People's Hospital of Leshan, Leshan, 614000, China.
2 Liver Transplantation Center, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, 610041, China.